Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12236381 | 0.90 | GPR119 (0.68) | GPR119CYP2C9 | |
| SCHEMBL12236506 | 0.89 | GPR119 (0.60) | GPR119CYP2C9 | |
| SCHEMBL12236436 | 0.87 | GPR119 (0.55) | GPR119 | |
| SCHEMBL12236537 | 0.86 | GPR119 (0.64) | GPR119CYP2C9 | |
| SCHEMBL13107758 | 0.84 | GPR119 (0.74) | GPR119CYP2C9 | |
| SCHEMBL12236432 | 0.82 | GPR119 (0.57) | GPR119CYP2C9 | |
| SCHEMBL12236383 | 0.82 | GPR119 (0.65) | GPR119CYP2C9 | |
| SCHEMBL12236406 | 0.82 | GPR119 (0.64) | GPR119CYP2C9 | |
| SCHEMBL12236375 | 0.81 | GPR119 (0.67) | GPR119CYP2C9 | |
| SCHEMBL12236379 | 0.81 | GPR119 (0.67) | GPR119CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382204-B1 | PYRIMIDINE DERIVATIVES AS GPCR MODULATORS FOR USE IN THE TREATMENT OF OBESITY AND DIABETES | MERCK SHARP & DOHME (US) | 2018-07-11 | — | — | EP | disclosed |
| US-8722882-B2 | Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes | MERCK SHARP & DOHME CORP. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722882-B2 | Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes | MERCK SHARP & DOHME CORP. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20110263570-A1 | PYRIMIDINE DERIVATIVES AS GPCR MODULATORS FOR USE IN THE TREATMENT OF OBESITY AND DIABETES | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263570-A1 | PYRIMIDINE DERIVATIVES AS GPCR MODULATORS FOR USE IN THE TREATMENT OF OBESITY AND DIABETES | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263570-A1 | PYRIMIDINE DERIVATIVES AS GPCR MODULATORS FOR USE IN THE TREATMENT OF OBESITY AND DIABETES | GPR119, GCGR, GPR65 | GPR119 1/4885CYP2C9 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.